XBI vs. CANC

Last updated Apr 2, 2026

Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and Tema Oncology ETF (CANC).

XBI and CANC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023.

Performance

XBI vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in SPDR S&P Biotech ETF (XBI) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

XBI vs. CANC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
XBI SPDR S&P Biotech ETF	5.43%	35.89%	1.01%	7.60%	-25.87%	-10.94%
CANC Tema Oncology ETF	6.91%	42.92%	-5.37%	510.51%	-85.34%	-51.82%

Returns By Period

In the year-to-date period, XBI achieves a 5.43% return, which is significantly lower than CANC's 6.91% return.

XBI

• 1D: 0.64%
• 1M: 1.58%
• YTD: 5.43%
• 6M: 27.21%
• 1Y: 65.07%
• 3Y*: 19.25%
• 5Y*: -1.16%
• 10Y*: 9.39%

CANC

• 1D: 1.16%
• 1M: -0.89%
• YTD: 6.91%
• 6M: 27.17%
• 1Y: 58.38%
• 3Y*: 140.92%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

XBI vs. CANC - Expense Ratio Comparison

XBI has a 0.35% expense ratio, which is lower than CANC's 0.75% expense ratio.

CANC

Tema Oncology ETF

XBI

SPDR S&P Biotech ETF

Return for Risk

XBI vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XBI

XBI Risk / Return Rank: 93
XBI Sharpe Ratio Rank: 93
XBI Sortino Ratio Rank: 94
XBI Omega Ratio Rank: 89
XBI Calmar Ratio Rank: 96
XBI Martin Ratio Rank: 95

CANC

CANC Risk / Return Rank: 92
CANC Sharpe Ratio Rank: 92
CANC Sortino Ratio Rank: 92
CANC Omega Ratio Rank: 86
CANC Calmar Ratio Rank: 95
CANC Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XBI vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XBI	CANC	Difference
Sharpe ratio Return per unit of total volatility	2.28	2.17	+0.11
Sortino ratio Return per unit of downside risk	2.99	2.84	+0.15
Omega ratio Gain probability vs. loss probability	1.38	1.36	+0.02
Calmar ratio Return relative to maximum drawdown	4.41	4.37	+0.04
Martin ratio Return relative to average drawdown	16.21	15.21	+1.00
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XBI vs. CANC - Sharpe Ratio Comparison

The current XBI Sharpe Ratio is 2.28, which is comparable to the CANC Sharpe Ratio of 2.17. The chart below compares the historical Sharpe Ratios of XBI and CANC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	XBI	CANC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.28	2.17	+0.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.04	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.36	-0.04	+0.40

Correlation

The correlation between XBI and CANC is 0.53, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

XBI vs. CANC - Dividend Comparison

XBI's dividend yield for the trailing twelve months is around 0.34%, more than CANC's 0.05% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
XBI SPDR S&P Biotech ETF	0.34%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

XBI vs. CANC - Drawdown Comparison

The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for XBI and CANC.

Drawdown Indicators

	XBI	CANC	Difference
Max Drawdown Largest peak-to-trough decline	-63.89%	-97.53%	+33.64%
Max Drawdown (1Y) Largest decline over 1 year	-13.39%	-12.40%	-0.99%
Max Drawdown (5Y) Largest decline over 5 years	-55.04%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-63.89%	—	—
Current Drawdown Current decline from peak	-25.70%	-55.68%	+29.98%
Average Drawdown Average peak-to-trough decline	-20.91%	-73.89%	+52.98%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.65%	3.57%	+0.08%

Volatility

XBI vs. CANC - Volatility Comparison

SPDR S&P Biotech ETF (XBI) has a higher volatility of 11.31% compared to Tema Oncology ETF (CANC) at 8.20%. This indicates that XBI's price experiences larger fluctuations and is considered to be riskier than CANC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XBI	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.31%	8.20%	+3.11%
Volatility (6M) Calculated over the trailing 6-month period	19.25%	16.22%	+3.03%
Volatility (1Y) Calculated over the trailing 1-year period	28.95%	27.19%	+1.76%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.23%	285.53%	-253.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.15%	285.53%	-253.38%